Drug name - Tepmetko
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(5 years from now) | |
| US8329692 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Oct, 2029
(7 years from now) | |
| US8580781 | EMD SERONO INC | Pyridazinone derivatives |
Mar, 2030
(7 years from now) | |
| CN101687857A | EMD SERONO INC | Pyrimidinyl Pyridazinone Derivative |
Apr, 2028
(5 years from now) | |
| CN101743241B | EMD SERONO INC | Pyridazinone Derivatives |
Apr, 2028
(5 years from now) | |
| CN101687857B | EMD SERONO INC | Pyridazinone Derivates |
Apr, 2028
(5 years from now) | |
| CN101743241A | EMD SERONO INC | Pyridazinone Derivates |
Apr, 2028
(5 years from now) | |
| IN281477B | EMD SERONO INC | Pyridazinone Derivatives |
Apr, 2028
(5 years from now) | |
| IN201000482P2 | EMD SERONO INC | Pyridazinone Derivatives |
Apr, 2028
(5 years from now) | |
| IN201000486P2 | EMD SERONO INC | Pyrimidinyl-Pyridazinone Derivates |
Jul, 2028
(5 years from now) | |
| IN273292B | EMD SERONO INC | Pyrimidinyl-Pyridazinone Derivatives |
Jul, 2028
(5 years from now) | |
| EP2754660A1 | EMD SERONO INC | Pyridazinone Derivatives |
Apr, 2028
(5 years from now) | |
| EP2164843B1 | EMD SERONO INC | Pyridazinone Derivates |
Apr, 2028
(5 years from now) | |
| EP2164843A1 | EMD SERONO INC | Pyridazinone Derivates |
Apr, 2028
(5 years from now) | |
| EP2754660B1 | EMD SERONO INC | Pyridazinone Derivatives |
Apr, 2028
(5 years from now) | |
| EP2164844A1 | EMD SERONO INC | Pyrimidinyl Pyridazinone Derivates |
Jul, 2028
(5 years from now) | |
| EP2164844B1 | EMD SERONO INC | Pyrimidinyl Pyridazinone Derivates |
Jul, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(5 years from now) | |
| US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(5 years from now) | |
| US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(5 years from now) | |
| US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(5 years from now) | |
| US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(5 years from now) | |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by administering an effective amount of tepotinib; Treating a solid tumor, including lung cancer, having a met kinase alteration(s) by administering an effective amount of tepotinib
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 225MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.